Sir Peter MacCallum Department of Oncology - Theses
Search
Search
Now showing items 1-10 of 69
Identification and molecular characterisation of high-risk pre-malignant breast lesions
(2019)
Mammographic screening has led to an increased detection of in situ and invasive breast carcinoma. However, lesions with uncertain malignant potential (B3) are also frequently detected with routine mammographic screening. ...
A Genome-wide RNAi screen identifies combinatorial efficacy of CX-5461 with homologous recombination deficiency and Topoisomerase I inhibition in ovarian cancer
(2019)
High-grade serous ovarian cancer (HGSC) is common, with poor prognosis. Limited therapeutic options are available, and the development of new therapies is of high priority. The RNA Polymerase I (Pol I) transcription inhibitor ...
The development, validation and application of novel preclinical models for the study of Barrett's carcinogenesis
(2019)
Oesophageal adenocarcinoma is an aggressive malignancy and is associated with extremely poor rates of survival. Its only known precursor is Barrett’s oesophagus, which is a metaplasia that occurs in the lower oesophagus ...
Novel combination therapies with the RNA Polymerase I-mediated transcription inhibitor CX-5461 improve efficacy in the treatment of multiple myeloma
(2019)
Multiple myeloma (MM) is a malignant plasma cell disorder that is incurable with currently available therapy. The disease is genetically heterogeneous, with many recurrently mutated genes only seen in small numbers of ...
Identification and validation of novel breast cancer predisposition genes
(2019)
The genetic causes of the majority of hereditary breast cancer families remain unresolved (BRCAx families) and lack of this information compromises primary and secondary cancer prevention for the affected women and their ...
Investigating the innate and adaptive immune response in patients with metastatic colorectal cancer
(2019)
The immune response is strongly associated with outcome in CRC (stages I-III). Cytotoxic CD8+ T-cells are the most important subset of immune cells positively associated with outcome, in most solid malignancies and especially ...
Exploration of novel regulators of mutant p53 in cancer cells: a role for NDFIP1
(2019)
Mutations in the tumour suppressor gene, TP53 occur in more than 50% of human cancers. Mutant p53 proteins not only lose their tumour suppressive capacities, but also gain oncogenic functions, broadly referred to as gain ...
Role of rDNA chromatin in sensitizing OVCA to RNA polymerase I transcription inhibitors
(2019)
The ribosomal RNA (rRNA) genes (rDNA) are arrayed in multiple tandem repeats on the 5 acrocentric chromosomes, and are transcribed by RNA Polymerase I (Pol I) which gives rise to the 47S pre-rRNA, the precursor of 18S, ...
Investigating the role of the Ras/MAPK pathway in increasing immunogenicity of triple negative breast cancers
(2019)
The predictive and prognostic significance of tumour infiltrating lymphocytes (TILs) has been highlighted in various solid cancers in recent years, where TIL infiltration has become a landmark biomarker of survival outcomes ...
Investigating epigenetic perturbations associated with DNMT3A and BCOR mutations in normal and malignant haematopoiesis
(2019)
Despite recent advances in cancer detection, molecular classification and treatment modalities, the 5-year survival rate of acute myeloid leukaemia (AML) has not changed in 30 years. The unique genetic context created by ...
RSS 1.0